Target
MDM2
28 abstracts
Abstract
Pre-clinical modeling of navtemadlin pharmacokinetics (PK), pharmacodynamics (PD), and efficacy in glioblastoma, IDH-wildtype.Org: Mayo Clinic, University of Minnesota, Brigham and Women's Hospital, Harvard Medical School,
Abstract
PK-PD-efficacy modeling of brigimadlin in MDM2-amplified glioblastoma.Org: Mayo Clinic, University of Minnesota, Boehringer Ingelheim,
Abstract
Proteomic analysis in patients with dedifferentiated liposarcoma (DDLPS) in a phase Ia/Ib study of the MDM2–p53 antagonist brigimadlin.Org: Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, Early Phase Clinical Trials Department, Maria Skłodowska-Curie National Research Institute and Oncology Centre,
Abstract
Treatment of patients with dedifferentiated liposarcoma (DDLPS) with the MDM2–p53 antagonist brigimadlin and p53 function: A longitudinal analysis of circulating microRNAs (miRNAs) in a first-in-human phase Ia/Ib study.Org: Boehringer Ingelheim Pharma GmbH & Co. KG, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, National Cancer Center Hospital East, Kashiwa, Japan, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland,
Abstract
A phase (Ph) 0/Ia study of brigimadlin concentration in brain tissue and a non-randomized, open-label, dose escalation study of brigimadlin in combination with radiotherapy (RT) in patients (pts) with newly diagnosed glioblastoma (GBM).Org: Boehringer Ingelheim España S.A., Venn Life Sciences,
Abstract
Genomic and biomarker analysis of immunotherapy combined with chemotherapy treated for patients with metastatic BTC cancer: A real world study.Org: Chinese People's Liberation Army General Hospital, Chinese People’s Liberation Army General Hospital, Senior Department of Oncology, The 5th Medical Center of the PLA General Hospital,
Abstract
The genomic and transcriptomic landscapes of chemotherapy naïve vs post-chemotherapy germ cell tumors.Org: University of California San Diego Health, CanSino Biologics, La Jolla, CA, UT Southwestern Medical Center, Txinno Bioscience,
Abstract
Genomic characterization of the GATA3 mutational landscape in breast cancer.Org: University of Texas MD Anderson Cancer Center, BostonGene Corporation, BostonGene Corp.,
Abstract
A phase 0/Ia study of BI 907828 concentrations in brain tissue and a nonrandomized, open-label, dose escalation study of BI 907828 in combination with radiotherapy in patients with newly diagnosed glioblastoma (GBM).Org: Mayo Clinic, Rochester Regional Health System, MN, Jacksonville, Flare Therapeutics,
Abstract
A phase IIa/IIb, open-label trial of BI 907828, an MDM2–p53 antagonist, in patients with locally advanced/metastatic biliary tract carcinoma or pancreatic ductal adenocarcinoma: Brightline-2.Org: Boehringer Ingelheim (People’s Republic of China) Investment Co., Ltd., Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH,
Abstract
Longitudinal mutational analysis of TP53 in plasma circulating tumor DNA (ctDNA) in patients (pts) with solid tumors in a phase I study of BI 907828, an MDM2–p53 antagonist.Org: Boehringer Ingelheim Pharma GmbH & Co. KG, Memorial Sloan Kettering Cancer Center, National Cancer Center Hospital East, Kashiwa, Japan, Sarah Cannon Research Institute/Tennessee Oncology, Florida Cancer Specialists & Research Institute,
Abstract
Association of C-MYC, MYC target gene, and unfolded protein response (UPR) expression with clinical benefit from the oral aurora kinase A (AURKA) inhibitor, alisertib (A), in combination with paclitaxel (P) compared with P alone in patients (Pts) with HER2-negative metastatic breast cancer (MBC).Org: Integrated Cancer Genomics Division, Translational Genomics Research Institute (TGen North), Phoenix, AZ, Translational Genomics Research Institute, Phoenix, AZ, Translational Genomics Research Institute (Phoenix, AZ),
Abstract
Biomarkers of response to sacituzumab govitecan (SG) and efficacy after treatment with enfortumab vedotin (EV) in advanced urothelial carcinoma (aUC): Analysis of the UNITE study.Org: University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, MD Anderson Hematology/Oncology Fellowship, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Washington and Fred Hutchinson Cancer Research Centre,
Abstract
A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with solid tumors: Safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS).Org: Yale University School of Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Memorial Sloan Kettering Cancer Center, Department of Experimental Therapeutics, National Cancer Center Hospital East, Sarah Cannon Research Institute/Tennessee Oncology,
Abstract
Feasibility and utility of the custom RNA-seq for the identification of therapeutic targets and diagnostic biomarkers in glioma.Org: Department of Neurosurgery and Neuro-Oncology, National Cancer Center Research Institute, Tokyo, Japan, National Cancer Center Hospital East, Kashiwa, Japan, Division of Cellular Signaling, National Cancer Center Research Institute, Department of Brain Disease Translational Research,
Abstract
A phase 2 study of alrizomadlin, a novel MDM2/p53 inhibitor, in combination with pembrolizumab for treatment of patients with malignant peripheral nerve sheath tumor (MPNST).Org: Ascentage Pharma Group, Ascentage Pharma (Suzhou) Co., Ltd., State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center Gansu Hospital,
Abstract
Exploratory novel biomarker and resistance mechanism of milademetan, an MDM2 inhibitor, in amplified MDM2 intimal sarcoma from an open-label phase 1b/2 trial (NCCH1806/MK004).Org: Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan, Wakayama Medical University Hospital, Wakayama, Japan, Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan, National Cancer Center Hospital, Tokyo, Japan, Department of International Clinical Development, National Cancer Center Hospital, Tokyo, Japan,
Abstract
Novel genomic alterations and transcriptomic-based tumor microenvironment classification of sarcoma and their impact on treatment decision making.Org: BostonGene, Corp., Waltham, MA, BostonGene Corporation, University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
NOTOS: A pivotal study of navtemadlin, a first-in-class mouse double minute 2 inhibitor (MDM2i), in patients (pts) with TP53 wild-type (TP53WT) Merkel cell carcinoma (MCC) for whom anti PD-1/L1 therapy has failed.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, University of Pittsburgh Medical Center, Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Rogel Cancer Center, University of Michigan, Aix-Marseille University CHU Timone,
Abstract
Cure-PROs: Next-generation targeted protein degraders.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, New York Oncology Hematology PC, MRP Pharma LLC, Chapel Hill, NC, Consultant,
Abstract
CCT6A and triple-negative breast cancer metastasis: Activating the AKT/MDM2/P53 pathway.Org: Department of Breast Cancer and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China, Fudan University Shanghai Cancer Center, Fudan University (Xiamen Branch), Department of Breast and Urological Medical Oncology, Fudan University Shanghai Cancer Center, Department of Breast and Urinary Oncology,
Abstract
Prognosis factors for long-term eribulin response in a cohort of patients with HER2-negative metastatic breast cancer.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, CHU Besançon, Besançon, Department of medical onclogy, Peking Union Medical College Hospital, Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,
Abstract
A phase 2 study of alrizomadlin (APG-115) in combination with pembrolizumab in patients with unresectable or metastatic cutaneous melanoma that has failed immuno-oncologic (IO) drugs.Org: University of Texas Health Science Ctr, San Antonio, TX, The University of Arizona Cancer Center, Tucson, AZ, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, Penn State Hershey Medical Center Cancer Institute, Hershey, PA, Sarah Cannon Research Institute at Tennessee Oncology, PLLC, Nashville, TN,
Abstract
The current state and future of neoadjuvants in resectable melanoma: Review of phase II/III studies conducted between 2018-2022.Org: University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, University Hospitals Cleveland Medical Center,
Abstract
A survey on the detection of HPD-related genes by liquid biopsy in patients with lung cancer in China.Org: Tianjin Medical University General Hospital, Tianjin, China, HaploX Biotechnology, Shenzhen, China, HaploX Biotechnology Co. Ltd.,
Abstract
Pan-cancer analysis of tumor mutation burden and other key ICI biomarkers in the Indian cohort.Org: Medanta Medicity, Gurugram, India, Max Super Speciality Hospital, Delhi, India, Max Super Speciality Hospital, Patiala, Punjab, India, Medical College of Wisconsin, Milwaukee, WI, Fortis Cancer Institute, New Delhi, India,
Abstract
Clinical benefit of personalized treatment following high throughput sequencing in metastatic melanoma: A national retrospective study.Org: Dermatology and Skin Cancer Department, AP-HM Marseille, Dermatology Departement, Cochin Hospital, APHP,Université Paris Cité, Paris, France, CHU de Bordeaux, Cochin Hospital,